Trial · NCT04196855
Study of Teriparatide in Stress Fracture Healing
NCT04196855, Phase 3, Unknown, University of East Anglia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Teriparatide in Stress Fracture Healing. Trials, record NCT04196855. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04196855
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Teriparatide in Stress Fracture Healing
- NCT number
- NCT04196855
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 136 participants, estimated
- Lead sponsor
- University of East Anglia
- Conditions
- Stress Fracture, Parathyroid Hormone
- Interventions
- Teriparatide
- First posted
- 2019-12-12
- Last updated
- 2020-11-04
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Radiological healing. | 8 weeks. | Radiological healing by 2 Grades or more, or to grade zero at 8 weeks. |
| Secondary | Radiological Healing | 8, 10, 12, 14, 16, 20, 24 weeks | Time to complete radiological healing |
| Secondary | Time from randomisation to assessed as 'Clinically Healed'. | Twice weekly from date of radiologically healed stress fracture reported on MRI scan up to 24 weeks | Physical assessment to commence once the fracture is reported as healed on MR. |
| Secondary | Time to 'Healing' as a composite assessment. | Up to 24 weeks. | Healing as assessed by MRI and clinical assessment. |
| Secondary | Time from randomisation to discharge from rehabilitation. | Up to 24 weeks | Completion of rehab will be assessed using Army standard measures. |
| Secondary | Pain symptoms on a visual analogue pain scale. | Diary to be completed weekly and analysed as a change from baseline to 16 weeks (24 weeks in an unhealed fracture). | Score between 0 and 10 - with 0 being no pain and 10 being worst pain imaginable. |
| Secondary | Difference in Quality of life | 4 weekly from baseline to 16 weeks | Assessed by Short Form 36 Questionnaire. The higher score, the better the participants quality of life. |
| Secondary | Adverse events | Up to 28 weeks. | As reported in accordance with CTAE Version 4.03 |
| Other | P1NP response to teriparatide treatment. | Base line then 4 weekly to week 16 - extorted to week 24 in the case of an unhealed fracture. | Measurement of bone marker of formation. |
| Other | CTX response to teriparatide treatment. | Base line then 4 weekly to week 16 - extorted to week 24 in the case of an unhealed fracture. | Measurement of bone marker of formation. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34461961 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04196855
GET https://conductscience.org/api/trials/v1/NCT04196855/registered